June, 2011 – GRI acquires exclusive worldwide rights to develop type I NKT cell inhibitor technology from the Torrey Pines Institute for Molecular Studies.
April, 2011 - GRI closes $200,000 seed round.
Feb, 2011 – GRI publishes Gastroenterology paper titled: “Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice.”
Jan, 2011 – GRI’s patent number 1940418 is granted in Europe.
October 2, 2009 - GRI names Albert Agro, Ph.D., as Chief Medical Officer.
July, 2009 - GRI acquires the exclusive worldwide rights to develop type II NKT cell technology from the Torrey Pines Institute for Molecular Studies.
May, 2009 - Glycoregimmune, Inc. (GRI) incorporates as a Delaware C corporation.